BioArctic AB announced today the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new research collaboration is intended to further characterize the unique binding profile of BAN2401. "We welcome the opportunity to join forces with Eisai in this initiative to generate additional knowledge about the unique properties of BAN2401. This may increase the understanding of the link between BAN2401's mechanism of action and the encouraging results achieved in the Phase 2b study in early Alzheimer's disease," comments BioArctic's CEO, Gunilla Osswald. Payments to BioArctic under this research collaboration total up to a potential EUR 3.25 million (approximately SEK 34 million). The research program is planned to continue through the end of June 2021 and results are expected to be presented at future scientific conferences. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!